AGC Biologics, a Japanese contract development and manufacturing organization (CDMO) specializing in biopharmaceuticals, is actively pursuing partnerships to secure clients for its upcoming Yokohama facility. Scheduled for completion in 2026, the plant will focus on producing antibody drugs, mRNA therapeutics, and cell therapies.

With extensive expertise across Japan, Europe, and the United States, AGC Biologics provides full-spectrum CDMO services, covering early development, clinical trials, and commercialization. The company’s capabilities span mammalian-based therapeutic proteins, microbial production, cell therapies, viral vectors, plasmid DNA, and mRNA.

At this year’s Bio Japan conference, AGC Biologics presented its Yokohama facility model and promoted its CDMO services to global industry leaders, highlighting the plant's competitive edge.

In an interview on October 11, Shigeru Kunii, Head of Business Development for AGC Biologics Asia, confirmed that they are actively partnering to secure international contracts for their seven production sites, including the Yokohama facility.

Kunii shared, “We conducted business meetings with both global pharma-biotech firms and Korean companies at Bio Japan. With the recent passage of the U.S. Biomanufacturing Act in the House, Japanese CDMO companies stand to benefit.”

He added, “AGC Biologics is expanding production capacity across facilities. Once operational, the Yokohama plant will be Japan’s largest antibody drug CDMO, further strengthening our capabilities across various modalities.”